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Abstract
Background: This article describes a pilot study evaluating a novel liquid biopsy
system for non-small cell lung cancer (NSCLC) patients. The electric field-
induced release and measurement (EFIRM) method utilizes an electrochemical
biosensor for detecting oncogenic mutations in biofluids.
Methods: Saliva and plasma of 17 patients were collected from three cancer cen-
ters prior to and after surgical resection. The EFIRM method was then applied to
the collected samples to assay for exon 19 deletion and p.L858 mutations. EFIRM
results were compared with cobas results of exon 19 deletion and p.L858 muta-
tion detection in cancer tissues.
Results: The EFIRM method was found to detect exon 19 deletion with an area
under the curve (AUC) of 1.0 in both saliva and plasma samples in lung cancer
patients. For L858R mutation detection, the AUC of saliva was 1.0, while the
AUC of plasma was 0.98. Strong correlations were also found between presurgery
and post-surgery samples for both saliva (0.86 for exon 19 and 0.98 for L858R)
and plasma (0.73 for exon 19 and 0.94 for L858R).
Conclusion: Our study demonstrates the feasibility of utilizing EFIRM to rap-
idly, non-invasively, and conveniently detect epidermal growth factor receptor
mutations in the saliva of patients with NSCLC, with results corresponding per-
fectly with the results of cobas tissue genotyping.
Introduction
Lung cancer is the most common cancer and leading cause
of cancer death in China and worldwide.1–8 Non-small cell
lung cancer (NSCLC) constitutes 80% of all lung cancer
cases, and is typically diagnosed at an advanced stage when
survival rates are low.9–15 The discovery of a relationship
between epidermal growth factor receptor (EGFR)-
activating mutations and EGFR-tyrosine kinase inhibitors
(TKI) has taken the treatment of patients with EGFR
mutations into an era of precision medicine.16–29 The 2009
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Iressa Pan-Asia Study (IPASS) demonstrated that EGFR-
TKIs are superior to traditional chemotherapeutic agents
for patients with EGFR mutant lung cancer, and the cur-
rent clinical EGFR-TKIs have become a standard first-line
treatment for patients with non-squamous NSCLC carry-
ing EGFR mutations.20 Genotyping for EGFR mutations in
advanced non-squamous NSCLC patients is highly recom-
mended in current clinical practice.
Epidermal growth factor receptor testing for mutations
is traditionally performed on tissues acquired by surgery or
biopsy. However, the majority of these diagnoses are on
late stage patients in poor physical condition. In these
instances, the performance of biopsy or surgery is often
impractical because of poor patient health and the risk of
additional clinical complications. Moreover, a high propor-
tion of NSCLC patients will develop EGFR-TKI treatment
resistance, and performing additional surgeries or biopsies
to monitor for an additional change in EGFR mutation sta-
tus would further increase the risk to patient health.21–26 As
a result of these limitations, explorations have been made
into the feasibility of detecting actionable EGFR oncogenic
mutations in biofluids, such as serum or plasma.3–8
Recent emerging work from the University of California,
Los Angeles (UCLA) has demonstrated the feasibility of
performing saliva-based EGFR mutation detection
(SABER) based on a core technology called electric field-
induced release and measurement (EFIRM).21 This method
is an electrochemical method based on immobilized
nucleic acid probes for capturing mutated sequences and
applying electric fields to facilitate the hybridization proc-
ess. Because of the speed and simplicity of the method,
EFIRM has the potential to be a suitable tool for oncogenic
mutation monitoring in a clinical context. Recently, a ran-
domized, blind study using SABER for NSCLC patients
demonstrated high concordance with tumor tissue based
genotyping.23 Here, we report the first clinical validation
pilot study of EFIRM in Mainland China.
Methods
Patients and clinical specimens
Inpatients with suspicious lesions for lung cancer, treated
at three large-scale major hospitals in China, West China
Hospital, Henan Cancer Hospital, and Jiangsu Cancer Hos-
pital, were recruited as subjects for our study. Each study
participant had 5 mL saliva and 10 mL blood collected
twice on the day before surgery, the day after surgery, and
approximately seven days after surgery. Blood plasma sam-
ples were collected by drawing blood into ethylenediamine-
tetraacetic acid tubes, centrifuging at 2500g for 10 minutes
at −4C, and then collecting the upper plasma layer. Sam-
ples were stored at −80 C until analysis. As per previous
studies in salivary biomarkers, saliva samples were kept on
ice during collection from patients and then centrifuged at
2600g for 15 minutes at 4C.22 The supernatant was removed
from the pellet, treated with RNase inhibitor (Superase-In,
Ambion Inc., Austin, TX, USA), and stored at −80C for
future analyses. All subjects provided informed consent.
Saliva-based epidermal growth factor
receptor (EGFR) mutation detection in
bodily fluids
Epidermal growth factor receptor mutations in serum and
saliva were detected by EFIRM in blinded samples by
trained laboratory personnel. Each plasma and saliva sam-
ple was measured in duplicate. Paired probes (capture and
detector; TsingKe, Beijing, China) specific to the two TKI-
sensitive mutations were used: for the exon 19 deletion
(19 del), a capture probe 50-TGT TGC TTC CTTGAT AGC
GAC G-30 and a detector probe 50-GGA ATT TTA ACT
TTC TCA CCT-FITC-30; for the L858R point mutation, a
capture probe: 50-CAG TTT GGC CCG CCC AAA ATC-
30and detector probe: 50-TTG ACA TGC TGC GGT GTT
TTC A-FITC-30. The detector probes were labeled with fluo-
rescein isothiocyanate. The EFIRM detection method
involves four primary steps.21 First, copolymerization of cap-
ture probes with pyrrole onto the bare gold electrodes by
applying a cyclic square wave electric. Second, hybridization
of the samples with detector and capture probes. Third,
the combination of anti-fluorescein antibody conjugated
to horseradish peroxidase (1:1000 dilution; Roche,
Indianapolis, IN, USA). Fourth, chromogenesis by 3,30, 5,50-
tetramethylbenzidine substrate for horseradish peroxidase
and measurement of the amperometric signal. The total
detection time of the protocol was less than 10 minutes, and
the procedure required 20 to 40 μL of the biological sample.
EGFR mutation detection in tumor tissues
Epidermal growth factor receptor mutations in tumor tis-
sues were detected by cobas assay, which is an allele-
specific real-time polymerase chain reaction (PCR) system
that qualitatively measures the amplification of DNA to
detect EGFR gene mutation from DNA derived from
freshly frozen tissues. DNA from these tissue specimens was
extracted according to the standard procedure delineated in
the cobas DNA Sample Preparation Kit (Roche Molecular
Systems Inc., Pleasanton, CA, USA).21 This processed
involved first incubating the sample with protease and buffer
ATL at 56C until dissolution. Buffer AL was then added for
an additional 10 minutes at 70C. Next, DNA samples were
collected by the DNeasy Mini spin column (Qiagen, Valen-
cia, CA, USA). After DNA samples were collected, the
amount of DNA was analyzed by spectrophotometer and
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adjusted to a concentration of 2 ng/μL. Finally, the prepared
DNA was amplified and detected by cobas 4800 (Roche
Molecular Systems Inc.) following the instructions for the
cobas EGFR mutation test. The results were automatically
reported in cobas 4800 software.
Statistical analysis
Receiver operating characteristic curves (ROC) and the area
under the curve (AUC) with 95% confidence intervals
(CI) were calculated to access the ability of EFIRM in detect-
ing EGFR mutations. Correlation coefficients were calculated
using Pearson parametric methods. All analyses were per-
formed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
The clinical characteristics of patients
A total of 17 randomized patients with adenocarcinoma
with EGFR mutation from three different cancer centers in
China (10 from West China Hospital, 4 from Henan Can-
cer Hospital, and 3 from Jiangsu Cancer Hospital) were
enrolled. The clinical characteristics of these patients,
including gender, age, smoking status, cancer stage, and
pathological type, are presented in Table 1.
Electric field-induced release and
measurement detection of EGFR mutations
in saliva and plasma
The strength of the amperometric currents detected by
EFIRM represented the status of the EGFR mutation. The
saliva samples of three patients taken prior to surgery
showed significantly higher currents using exon 19 probes,
which meant that they were detected to have EGFR exon
19 del mutations (Fig 1a; 85.3  0.3 nA in the exon 19 del
group vs. 51.2  5.6 nA in the L858R mutant and
49.7  7.4 nA in the wild-type; P < 0.01). Similarly, three
patients, whose saliva samples had higher current readouts
on EFIRM using the L858R mutant probes, were detected
to harbor EGFR L858R mutants (Fig 1b; 114.9  26.5 nA
in the L858R mutant group vs. 45.6  0.2 nA in the exon
19 del and 53.6  12.0 nA in the wild-type; P < 0.01). This
detection included the samples collected both before and
after surgery to avoid the possibility of tumor cells or DNA
dropping into the circulation system by outside forces, and
the results showed high consistency (Figs 1a, 2a and 1b,
2b). ROC analysis indicated AUCs of 1 for the probe carry-
ing the exon 19 del and L858R mutation (Figs 1c, 2c).
Plasma samples were collected before and after surgery
by EFIRM, except in one patient who only had samples
taken after surgery. The results showed three exon 19 dele-
tions (Fig 3a, 85.6  9.6 nA in the exon 19 del group vs.
Table 1 The clinical characteristics of patients in the study
Patient No. Gender Age Smoking status Histologic type Stage†
EGFR status
Cobas
EFIRM
Saliva Plasma
Before After Before After
1 M 76 N NSCLC pT2bN0M0, IIA No No No No No
2 M 53 Y Adeno pT2aN1M0, IIA Ex19 del Ex19 del Ex19 del Ex19 del Ex19 del
3 M 53 Y Squa pT2bN0M1a, IV No No No No No
4 M 53 Y Adeno pT2bN2M0, IIIA Ex19 del Ex19 del Ex19 del Ex19 del Ex19 del
5 M 65 Y Squa pT3N0M0, IIB No No No No No
6 F 72 N NSCLC pT3N0M0, IIB G719X No No No No
7 M 71 Y Adeno PT2aN0M0, IB L858R L858R L858R L858R L858R
8 M 46 Y Adeno pT3N3M0, IIIB No No No No No
9 M 57 Y Squa pT4N0M0, IIIA No No No No No
10 F 61 N Adeno pT2aN20M, IIIA Ex19 del NE Ex19 del NE Ex19 del
11 M 47 Y Adeno pT2bN2M0, IIIA No No No No No
12 M 62 Y Squa pT2aN0M0, IB No No No No No
13 F 51 N Adeno pT2aN0M0, IIB L858R L858R L858R L858R L858R
14 M 71 N Squa pT1aN1M0, IIA No No No No No
15 M 50 N Adeno pT2N2M0, IIIA No No No L858R L858R
16 M 60 Y Squa pT2N0M0, IB No No No No No
17 M 51 N Adeno pT2N2M0, IIIA L858R L858R L858R L858R L858R
†Stage was based on National Comprehensive Cancer Network guidelines 2014, V3. Adeno, adenocarcinoma; EGFR, epidermal growth factor recep-
tor; EFIRM, electric field-induced release and measurement; F, female; M, male; NE, no samples; NSCLC, non-small cell lung cancer; Squa, squamous
lung cancer.
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48.9  8.0 nA in the L858R mutant and 51.1  9.5 nA in
the wild-type; P = 0.001) and four L858R mutations
(Fig 4a, 111.4  27.8 nA in the L858R mutant group vs.
46.2  0.7 nA in the exon 19 del and 51.9  11.8 nA in
the wild-type; P < 0.001) before surgery. Similar results
were obtained from plasma collected after surgery (Fig 3b,
92.6  18.8 nA in the exon 19 del group vs.
52.9  6.1 nA in the L858R mutant and 51.8  5.4 nA in
the wild-type; P < 0.001; Fig 4b, 108.9  22.2 in the L858R
mutant group vs. 45.9  1.7 nA in the exon 19 del and
52.4  13.6 nA in the wild-type; P < 0.001). The AUCs
are shown in Fig 4c, respectively.
Cobas detection of EGFR mutations in
tumor tissues
As a result of the approval of cobas for clinical use by the
United States Food and Drug Administration and the
China Food and Drug Administration, cobas assay is used
as the gold standard method of EGFR mutation detection.
We detected 17 tissue samples and found six samples har-
boring EGFR mutation (35.3%; 3 exon 19 del and 3 L858R
mutations). We compared the results from EFIRM assay
using saliva and plasma with the cobas assay using tumor
tissues to evaluate the sensitivity and specificity of EFIRM
assay in detecting EGFR mutation. The saliva and plasma
samples of three patients that were identified to harbor
EGFR exon 19 del with EFIRM were confirmed by cobas
assay. Furthermore, these three patients with EGFR L858R
mutations also perfectly matched the mutation results for
saliva, plasma, and tissue samples. The other 11 patients
were EGFR wild-type in both saliva and tissue samples,
which meant that there was a single false positive L858R
mutation in plasma sample detection by EFIRM. The spec-
ificity and sensitivity was 90.9% and 100%, respectively, by
plasma. In addition, all of the patients with EGFR muta-
tion were histologically diagnosed with adenocarcinoma
(3 stage III, 2 stage II, and 1 stage I), which indicated that
EFIRM assay could maintain a high sensitivity in different
cancer stages.
Figure 1 Blinded and randomized detection of epidermal growth factor receptor (EGFR) mutations by electric field-induced release and measure-
ment assay in saliva collected before surgery from patients with non-small cell lung cancer: (a) the probe for EGFR exon 19 deletion in saliva; (b) the
probe for L858R in saliva; and (c) receiver operating characteristic curves for detecting EGFR exon 19 deletion (area under the curve [AUC] = 1) and
L858R mutations (AUC = 1), respectively.
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The correlation of EGFR mutation detected
before and after surgery
We compared the results from the saliva and plasma col-
lected before and after surgery to evaluate whether surgery
affected EGFR mutation status. The strength of the
amperometric currents in the saliva samples collected
before surgery correlated with those after surgery using the
L858R and exon 19 probes (Table 2, R = 0.86 in exon
19 del; R = 0.98 in L858R). Similar results were obtained
in plasma samples (Table 2, R = 0.73 in exon 19 del;
R = 0.94 in L858R). Additionally, regardless of whether
samples were collected before or after surgery, the ampero-
metric currents between saliva and plasma had a strong
correlation (Table 2, before surgery: R = 0.87 in exon
19 del and R = 0.67 in L858R; after surgery: R = 0.79 in
exon 19 del and R = 0.70 in L858R).
Discussion
Liquid biopsy to detect actionable mutations in NSCLC in
clinical practice is primarily based on digital droplet PCR
(ddPCR) and/or next generation sequencing technologies
with performance at ~70–80% concordance with tissue-
based genotyping. Technologies that will permit 100% con-
cordance detection (sensitivity) will provide the ultimate
complementation to the tumor-specific fingerprint (speci-
ficity) for unambiguous detection of the tumor in a non-
invasive setting.3–14 To our knowledge, this is the first pilot
study aimed at evaluating a novel saliva-based EGFR muta-
tion detection system for lung cancer in Mainland China.
Our findings clearly show that saliva and plasma assays
conducted using the EFIRM method have high concord-
ance with biopsy tissue-based testing for lung cancer EGFR
mutation status. EFIRM liquid biopsy is accurate, non-
Figure 2 Blinded and randomized detection of epidermal growth factor receptor (EGFR) mutations by electric field-induced release and measure-
ment assay in saliva collected after surgery from patients with non-small cell lung cancer: (a) the probe for EGFR exon 19 deletion in saliva; (b) the
probe for L858R in saliva; and (c) receiver operating characteristic curves for detecting EGFR exon 19 deletion (area under the curve [AUC]= 1) and
L858R mutations (AUC = 1), respectively.
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invasive, and rapid. It is can be used in continuous moni-
toring EGFR mutation status during EGFR-TKI treatment.
We demonstrated that the amperometric currents of the
EFIRM signals from saliva were highly correlated with
those from plasma using the probe designed for p.E746-
A750del and p.L858R, regardless of whether the sample
was collected presurgery or post-surgery (0.70s range).
These results suggest that the amount of EGFR mutant
DNA in saliva and plasma is correlated. This may have a
mechanistic implication, suggesting a link between the
peripheral circulatory system and the salivary glands. Pre-
vious studies of this link have also found similarly strong
correlations.22 However, the precise mechanism by which
lung cancer cells release the EGFR mutant DNA and dis-
perse it via the blood to distal sites remains to be
established.
Another interesting finding in our study was the strong
correlations found between presurgery and post-surgery
saliva assays (0.86 and 0.98) and plasma (0.73 and 0.94).
This data implies that surgery may not influence EGFR
mutant DNA status in saliva or plasma. Saliva collected
after biopsy may result in tumor cells or cell-free DNA that
make their way into the saliva after tissue disruption,
demonstrating that the detection of EGFR mutation in
saliva was not a result of biopsy materials leaking into
saliva.
Although this cohort of tests was only conducted on a
small scale, there were still overlapping current values of
EGFR wild type and mutation type at exon 21 L858R in
plasma, which may have led to false-positive results. Previ-
ous studies have demonstrated a similar phenomenon at
L858R with an unclear threshold between wild type and
mutation type.22 A large prospective study will be con-
ducted to determine the adequate and optimal estimate of
a threshold to decide the balance between false positive
and false negative rates.
Electric field-induced release and measurement can
detect EGFR mutations in liquid biopsy from NSCLC
Figure 3 Blinded and randomized detection of epidermal growth factor receptor (EGFR) mutations by electric field-induced release and measure-
ment assay in plasma collected before surgery from patients with non-small cell lung cancer: (a) the probe for EGFR exon 19 deletion; (b) the probe
for L858R; and (c) receiver operating characteristic curves for detecting EGFR exon 19 deletion (area under the curve [AUC]= 1) and L858R mutations
(AUC = 0.98), respectively.
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patients, but at present this work has mainly focused on
EGFR L858R and exon 19 del mutations. Because the sec-
ond T790M EGFR mutation accounts for half of the TKI-
resistant cases, monitoring the T790M mutation would be
useful to estimate EGFR-TKI resistance. Therefore, devel-
opment of a new probe designed for EFIRM based on
T790M mutation is necessary, and this approach, as with
other liquid biopsy-based EGFR mutation assays (such as
circulating tumor cells or cell-free circulating tumor DNA),
might be a valid noninvasive alternative to biopsy, as well
as a better tailoring of individualized precision therapy by
monitoring the response to treatment in NSCLC patients.
In conclusion, our results provide evidence that EFIRM
detection of EGFR mutation in the saliva of patients with
lung cancer is accurate, non-invasive, and rapid.
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